Moderna, Inc. hasn’t disclosed how much it hopes Pfizer Inc. and BioNTech SE will pay if it wins its patent infringement suit accusing them of copying the messenger RNA (mRNA) technology it used to develop Spikevax in their own COVID-19 vaccine, Comirnaty. But it appears less interested in giving Spikevax a leg up on the market than in ensuring it maintains control over the underlying intellectual property fueling its rapidly expanding pipeline – as well as BioNTech’s.
Moderna’s Suit Against Pfizer/BioNTech Is About More Than Money
Moderna is seeking financial compensation for Comirnaty in its patent infringement suit, but it seems especially keen to assert IP rights over what could become an even more valuable platform technology.
More from R&D
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.